Orion OYJ (OTCMKTS:ORINY – Get Free Report) and Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Risk and Volatility
Orion OYJ has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, Jupiter Neurosciences has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Orion OYJ and Jupiter Neurosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orion OYJ | 0 | 2 | 1 | 0 | 2.33 |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Orion OYJ | 27.14% | 49.17% | 28.54% |
| Jupiter Neurosciences | N/A | -1,314.62% | -228.63% |
Earnings & Valuation
This table compares Orion OYJ and Jupiter Neurosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orion OYJ | $2.14 billion | 5.09 | $566.04 million | $2.18 | 17.68 |
| Jupiter Neurosciences | $20,000.00 | 323.80 | -$8.65 million | ($0.27) | -0.66 |
Orion OYJ has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.
Summary
Orion OYJ beats Jupiter Neurosciences on 9 of the 11 factors compared between the two stocks.
About Orion OYJ
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Orion OYJ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion OYJ and related companies with MarketBeat.com's FREE daily email newsletter.
